Overview

(+) Epicatechin to Treat Friedreich's Ataxia

Status:
Completed

Trial end date:
2018-12-30

Target enrollment:

Participant gender:

Summary

This 24-week study will test the safety and effectiveness of synthetically produced (+) Epicatechin in treating patients who have Friedreich's Ataxia, a neurological disorder.

Phase:

Phase 2

Details

Lead Sponsor:

Ralitza Gavrilova

Collaborator:

Cardero Therapeutics, Inc.